In this video, Motley Fool health-care analyst David Williamson takes a look at Threshold's (NASDAQ: THLD ) big week and the news on Friday that has shares soaring even higher. Find out what it means for investors in Threshold and competitor Celgene if MAESTRO is a success.
With Celgene's broad portfolio of drugs and a strong pipeline to boot, many investors see it as a smarter way to play the biotech investing game. While Celgene might be a safer stock than its small biotech brethren, investors need to know about the key opportunities and risks facing the company. We run through them all in The Motley Fool's brand new premium report on Celgene. To claim your copy today, simply click here now.